The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Merger | Merged

Total Raised


About EpiCept

EpiCept is focused on unmet needs in the treatment of pain and cancer. The Company's portfolio of pharmaceutical product candidates includes several pain therapies in clinical development and a lead oncology compound for AML with demonstrated efficacy in a Phase III trial; a marketing authorization application for this compound is approaching a decision in Europe. In addition, EpiCept's ASAP technology, a proprietary live cell high-throughput caspase-3 screening technology, can efficiently identify new cancer drug candidates and molecular targets that selectively induce apoptosis in cancer cells. Two oncology drug candidates currently in clinical development that were discovered using this technology have also been shown to act as vascular disruption agents in a variety of solid tumors.

EpiCept Headquarter Location

777 Old Saw Mill River Road

Tarrytown, New York, 10591,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing EpiCept

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

EpiCept is included in 1 Expert Collection, including Cancer.



1,179 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

EpiCept Patents

EpiCept has filed 1 patent.

patents chart

Application Date

Grant Date


Related Topics




Transcription factors, Programmed cell death, Triazines, Proteins, EC 3.4.22


Application Date


Grant Date



Related Topics

Transcription factors, Programmed cell death, Triazines, Proteins, EC 3.4.22



Latest EpiCept News

Immune Pharmaceuticals Inc IMNP Financial and Strategic SWOT Analysis Review Report Updated 07082017 Prices from USD $300

Aug 20, 2017

Printed From Immune Pharmaceuticals Inc IMNP Financial and Strategic SWOT Analysis Review [Report Updated: 07082017] Prices from USD $300 18:34 EDT 20 Aug 2017 | BioPortfolio Reports Home » Topics » Antibodies » Latest News » Immune Pharmaceuticals Inc IMNP Financial and Strategic SWOT Analysis Review [Report Updated: 07082017] Prices from USD $300 Summary Immune Pharmaceuticals Inc Immune Pharma formerly EpiCept Corporation, is a pharmaceutical company that develops antibody therapeutics for the treatment of patients with inflammatory diseases and cancer . The company's bertilimumab is under clinical development for moderate to severe ulcerative colitis , crohn's disease and bullous pemphigoid. It also offers nanomabs, which is an antibody nanoparticle conjugate technology platform for the targeted delivery of chemotherapeutics. Immune Pharma's crolibulin is a small molecule vascular disrupting agent that is used for the treatment of solid tumors. The company develops drugs in the areas of immuno oncology, nanodermatology and neuropathic pain. It has research and development facility in HerzliyaPituach, Israel. Immune Pharma is headquartered in New York, the US. Immune Pharmaceuticals Inc Key Recent Developments Jul 19,2017: Immune Pharmaceuticals Provides Update on Plan to Implement a Spinoff of Cytovia into a Separate Publicly Traded Oncology Company Apr 24,2017: Immune Pharmaceuticals Announces Corporate Restructuring Mar 13,2017: Immune Pharmaceuticals Granted Additional Time to Comply with Nasdaq Listing Requirement Jan 27,2017: Immune Pharmaceuticals Appoints New Chairman of the Board of Directors Oct 17,2016: Immune Pharmaceuticals Announces Formation of Management Team for Maxim Pharmaceuticals, its Pain and Neurology Subsidiary This comprehensive SWOT profile of Immune Pharmaceuticals Inc provides you an indepth strategic analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better. This company report forms part of GlobalData's Profile on Demand' service, covering over 50,000 of the world's leading companies. Once purchased, GlobalData's highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Immune Pharmaceuticals Inc including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. excluding weekends. The profile contains critical company information including*, x000D x000D Business description A detailed description of the company's operations and business divisions.x000D Corporate strategy Analyst's summarization of the company's business strategy.x000D SWOT Analysis A detailed analysis of the company's strengths, weakness, opportunities and threats.x000D Company history Progression of key events associated with the company.x000D Major products and services A list of major products, services and brands of the company.x000D Key competitors A list of key competitors to the company.x000D Key employees A list of the key executives of the company.x000D Executive biographies A brief summary of the executives' employment history.x000D Key operational heads A list of personnel heading key departments/functions.x000D Important locations and subsidiaries A list and contact details of key locations and subsidiaries of the company.x000D Key manufacturing facilities A list of key manufacturing facilities of the company.x000D Detailed financial ratios for the past five years The latest financial ratios derived from the annual financial statements published by the company with 5 years history.x000D Interim ratios for the last five interim periods The latest financial ratios derived from the quarterly/semiannual financial statements published by the company for 5 interims history.x000D x000D Note*: Some sections may be missing if data is unavailable for the company. Key benefits of buying this profile include,x000D x000D You get detailed information about the company and its operations to identify potential customers and suppliers.x000D The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.x000D x000D Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.x000D The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events. x000D x000D Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.x000D Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.x000D x000D Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.x000D Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.x000D x000D Gain key insights into the company for academic or business research.x000D Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs. Related Biotechnology, Pharmaceutical and Healthcare News

  • When was EpiCept founded?

    EpiCept was founded in 1993.

  • Where is EpiCept's headquarters?

    EpiCept's headquarters is located at 777 Old Saw Mill River Road, Tarrytown.

  • What is EpiCept's latest funding round?

    EpiCept's latest funding round is Merger.

  • How much did EpiCept raise?

    EpiCept raised a total of $66.85M.

  • Who are the investors of EpiCept?

    Investors of EpiCept include ATP Capital and Via Venture Partners.

  • Who are EpiCept's competitors?

    Competitors of EpiCept include Adamas Pharmaceuticals, Asteres, Stemina Biomarker Discovery, Esperance Pharmaceuticals, OncoMed Pharmaceuticals, Intarcia Therapeutics, PNP Therapeutics, Helomics, Eiger BioPharmaceuticals, U3 Pharma and 27 more.

You May Also Like

Esperance Pharmaceuticals

Esperance Pharmaceuticals develops targeted anticancer drugs that selectively kill cancer cells without harming normal cells.

Marillion Pharmaceuticals

Marillion Pharmaceuticals, Inc. - Marillion is developing clinical-stage drugs in oncology and oncology supportive care. 177Lu-AMBA is a targeted radiotherapeutic, with the low level radiation of lutetium that aims to utilize an receptor-based technology, and can serve as both a diagnostic and therapeutic agent. The targeting capability means that 177Lu-AMBA homes in on tumor cells and spares normal tissues. 177Lu-AMBA is being pursued initially to treat hormone-resistant prostate cancer, has been studied in a phase I trial in Europe. Marillion also is developing PilobucTM , buccal formulation of pilocarpine ,for the treatment of dry mouth, shown in clinical trials to effectively and conveniently deliver the drug with reduced side effects compared to other routes of administration.PilobucTM buccal formulation of pilocarpine has the potential to be a product in the xerostomia market. Marillion is preparing for phase II trials of the product candidate..


Apoptos, Inc. is focused on discovering and developing effective, targeted small-molecule anticancer drugs that activate apoptosis (programmed cell death).


Onyvax is developing new cancer therapies that harness the selective power of the immune system to seek out and destroy tumor cells. Onyvax's products specifically target cancer cells, increasing the likelihood that they will be effective while minimising side effects associated with many conventional treatments. These therapies can broadly be classed as therapeutic cancer vaccines. Onyvax's lead product is in clinical trials for the treatment of prostate cancer and is poised to enter the final stages of development. Onyvax is committed to the commercialisation of therapies that enhance survival while maintaining a high quality of life for patients. The Company is based in London and has collaborations with leading hospitals and other institutions throughout Europe and the US.


Neotropix 1 is a virotherapy company, dedicated to the development and commercialization of virus-based therapies for the treatment of cancer and other diseases. Per Neotropix, virotherapy holds great promise for cancer patients because it may be more efficacious and less toxic than conventional radiation and chemotherapy.


NovoCell, Inc./BresaGen is a stem cell engineering company dedicated to creating, delivering, and commercializing cell and drug therapies to treat diabetes and other chronic diseases. Novocell uses its cell encapsulation technology and expertise in cell implantation to develop a renewable source of specialized cells for the treatment of cellular diseases. Bresagen represents a division of Novocell's research operation.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.